JSK Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

JSK Therapeutics General Information

Description

Developer of anti-cancer therapeutics designed to reduce pain and suffering by using chemistry against cancer. The company's therapeutics offer nitric oxide (NO)-generating compounds of the arylated diazeniumdiolate class and also develop initiatives for the treatment of acute myeloid leukemia and multiple myeloma, enabling doctors to treat and improve cancer patients' lives with fewer side effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 47 West 200 South
  • Suite 101
  • Salt Lake City, UT 84101
  • United States
+1 (801)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 47 West 200 South
  • Suite 101
  • Salt Lake City, UT 84101
  • United States
+1 (801)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

JSK Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private Completed Pre-Clinical Trials
11. Later Stage VC 30-Jun-2022 Completed Pre-Clinical Trials
10. Grant 01-Jan-2018 Completed Pre-Clinical Trials
9. Later Stage VC 11-Dec-2017 Completed Pre-Clinical Trials
8. Grant 21-Sep-2017 Completed Pre-Clinical Trials
7. Grant 01-Jan-2014 Completed Startup
6. Grant 01-Jan-2012 Completed Startup
5. Grant 01-Jan-2010 Completed Startup
4. Seed Round 07-Nov-2008 $325K $325K Completed Startup
3. Grant $1.7M Completed Startup
To view JSK Therapeutics’s complete valuation and funding history, request access »

JSK Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view JSK Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

JSK Therapeutics Patents

JSK Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3091516-A1 Composition and method for topical js-k as therapy for actinic keratosis Inactive 18-Feb-2018
US-20190255040-A1 Composition and method for topical js-k as therapy for actinic keratosis Inactive 18-Feb-2018
WO-2019161396-A1 Composition and method for topical js-k as therapy for actinic keratosis Inactive 18-Feb-2018 A61K31/495

JSK Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

JSK Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cephalon Corporation Minority
Utah Centers of Excellence Government
National Cancer Institute Government
University of Utah University Minority
To view JSK Therapeutics’s complete investors history, request access »

JSK Therapeutics FAQs

  • When was JSK Therapeutics founded?

    JSK Therapeutics was founded in 2008.

  • Where is JSK Therapeutics headquartered?

    JSK Therapeutics is headquartered in Salt Lake City, UT.

  • What is the size of JSK Therapeutics?

    JSK Therapeutics has 6 total employees.

  • What industry is JSK Therapeutics in?

    JSK Therapeutics’s primary industry is Drug Discovery.

  • Is JSK Therapeutics a private or public company?

    JSK Therapeutics is a Private company.

  • What is JSK Therapeutics’s current revenue?

    The current revenue for JSK Therapeutics is .

  • How much funding has JSK Therapeutics raised over time?

    JSK Therapeutics has raised $6.29M.

  • Who are JSK Therapeutics’s investors?

    Cephalon, Utah Centers of Excellence, National Cancer Institute, and University of Utah have invested in JSK Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process